ERYTECH Pharma S.A.
ERYP · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $39 | $34 | $44 | $73 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $3 | $4 | $4 | -$2 |
| Inventory | $1 | $0 | $0 | $0 |
| Other Curr. Assets | $0 | $0 | $0 | $10 |
| Total Curr. Assets | $43 | $40 | $50 | $82 |
| Property Plant & Equip (Net) | $3 | $26 | $29 | $36 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $1 | $1 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $1 |
| Other NC Assets | $0 | $1 | $1 | $0 |
| Total NC Assets | $3 | $27 | $31 | $37 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $46 | $67 | $80 | $119 |
| Liabilities | – | – | – | – |
| Payables | $2 | $2 | $5 | $5 |
| Short-Term Debt | $3 | $2 | $4 | $2 |
| Tax Payable | $0 | $4 | $4 | $4 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $7 | $12 | $16 | $10 |
| Total Curr. Liab. | $12 | $20 | $29 | $20 |
| LT Debt | $10 | $23 | $24 | $13 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $1 | $1 | $1 |
| Total NC Liab. | $11 | $24 | $25 | $13 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $22 | $44 | $54 | $33 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $3 | $3 | $2 | $2 |
| Retained Earnings | -$0 | -$54 | -$73 | -$63 |
| AOCI | -$28 | -$24 | -$23 | -$135 |
| Other Equity | $49 | $98 | $121 | $282 |
| Total Equity | $23 | $23 | $27 | $86 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $46 | $67 | $80 | $119 |
| Net Debt | -$25 | -$8 | -$17 | -$59 |